| less than a minute read
Park Square Places Richard Wenstrup, M.D. as Chief Medical Officer at Oxford Immunotec
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the appointment of Richard Wenstrup, MD, as Chief Medical Officer. Dr. Wenstrup brings to Oxford Immunotec more than 20 years of clinical leadership experience, including over a decade within the diagnostics industry. Most recently, Dr. Wenstrup served as Executive Vice President, Chief Medical Officer, for Myriad Genetics, Inc., where he played a key leadership role and made substantial contributions across the company that helped drive and support a multi-fold increase in revenue over a decade. In addition to building and leading Myriad’s clinical and medical affairs teams, Dr. Wenstrup was actively involved in the company’s product development, M&A, and in-licensing activities. He also previously served as Chief Medical Officer for Myriad Genetic Laboratories, Inc.

/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-23-14-44-49-507-6ab3e5e1470f335536fcf89c.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-22-15-19-50-498-6ab29c96af556e9074387689.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-15-18-23-35-620-6aa98d270810fd5205abd644.png)